POS-496 INTERIM ANALYSIS OF THE EAGLE TRIAL: AN OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

• R. Torra Balcells,
• G. Appel B,
• B. Fischbach,
• N. Kandai,
• B. Knebelmann,
• K. Lieberman,
• C. Meyer J,
• D. Packham M,
• A. Rastogi,
• D. Rizk V,
• A. Silva L,
• B. Spinowitz,
• S. Sprague M,
• P. Zaoui,
• P. Pergola E

Affiliations

R. Torra Balcells

Universitat Autonoma de Barcelona, Nephrology Department, Barcelona, Spain

G. Appel B

Columbia University College of Physicians and Surgeons, Department of Medicine- Division of Nephrology, New York City, United States

B. Fischbach

Dallas Nephrology Associates, Renal Disease Research Institute, Dallas, United States

N. Kandai

Kobe University Graduate School of Medicine, Department of Pediatrics, Kobe, Japan

B. Knebelmann

Necker Hospital, Department of Nephrology, Paris, France

K. Lieberman

Hackensack Meridian School of Medicine, Department of Pediatrics, Hackensack, United States

C. Meyer J

Reata Pharmaceuticals, Department of Product Development, Plano, United States

D. Packham M

University of Melbourne, Department of Medicine, Melbourne, Australia

A. Rastogi

University of California at Los Angeles Medical Center, Division of Nephrology, Los Angeles, United States

D. Rizk V

University of Alabama at Birmingham, Division of Nephrology, Birmingham, United States

A. Silva L

Boise Kidney and Hypertension Institute, Nephrology, Boise, United States

B. Spinowitz

New York Presbyterian Queens, Department of Medicine- Division of Nephrology, Flushing, United States

S. Sprague M

Northshore Medical University Health System - University of Chicago, Division of Nephrology and Hypertension, Evanston, United States

P. Zaoui

CHU Grenoble Alpes, Nephrology Clinic, Grenoble, France

P. Pergola E

Renal Associates PA, Renal Associates PA, San Antonio, United States